Chordia Therapeutics Inc. [190A.T]
TOKYO, May 01 (Pulse News Wire) – Chordia Therapeutics Co., Ltd. (190A.T) reported the exercise status of its ninth tranche warrant for April 2026.
According to the report, during the month of April, 116 shares were delivered based on exercised warrants out of a total issuance of 1,196,000. A total of 11,960 warrants were exercised, representing 11.59% of the total issuance. As of the end of March 2026, there were 46,084 unexercised warrants remaining, which decreased to 34,124 by the end of April. Detailed exercise activities for April included several key dates: - On April 1, 15,000 shares were transferred, exercising 116 warrants at a price of ¥5,000 per share. - On April 6, another 15,000 shares were transferred, exercising 118 warrants at a price of ¥150 per share. - On April 15, 800 warrants were exercised without transferring any shares. - On April 16, 190,000 shares were transferred, exercising 124 warrants at a price of ¥1,900 per share.
- On April 17, 123 warrants were exercised without transferring any shares. - On April 20, 2,000 warrants were exercised without transferring any shares. - On April 22, 15,000 shares were transferred, exercising 150 warrants at a price of ¥150 per share. - On April 28, 5,000 shares were transferred, exercising 50 warrants at a price of ¥50 per share. As of the end of March 2026, the outstanding share count was 75,216,400 (including no treasury shares). The company adhered to the exercise limitations set forth by the Tokyo Stock Exchange's "Rules Governing the Issuance and Trading of Securities Listed on the Exchange," maintaining an exercise ratio of 1.73%. For more detailed information on the issuance of the ninth tranche warrant, refer to the press release dated September 5, 2025.
🟡 Confidence: Standard AI-translated content.